Economic Burden of Human Papillomavirus-Related Diseases in Italy

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Baio, Gianluca ^a,b   Capone, Alessandro ^c   Marcellusi, Andrea ^d   Mennini, Francesco Saverio ^c,d   Favato, Giampiero ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c KINGSTON UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS CANCER; ARTICLE; CANCER INVASION; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; ITALY; OUTCOMES RESEARCH; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PREVALENCE; RECURRENT INFECTION; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA CANCER; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; VULVA CANCER;

CONDYLOMATA ACUMINATA; FEMALE; HEALTH CARE COSTS; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; ITALY; MALE; MODELS, ECONOMIC; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RESEARCH DESIGN; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84869853111     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049699     Document Type: Article

References (62)

1. Wiley DA, Mansongsong E, (2006) Human papillomavirus: the burden of infection. Obstet Gynecol Surv 61: S3-S14.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1): 12-9.
3. Clifford GM, Smith JS, Plummer M, Franceschi S, (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88(1): 63-73.
4. Chaturvedi AK, (2010) Beyond cervical cancer: burden of other HPV-related cancers among men and women. Journal of Adolescent Health 46: S20-S26.
5. Koutsky LA, Galloway DA, Holmes KK, (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10: 122-163.
6. Von Krogh G, (2001) Management of anogenital warts (condylomata acuminata). Eur J Dermatol 11(6): 598-603.
7. Armstrong LR, Derkay CS, Reeves WC, (1999) Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 125(7): 743-748.
8. Armstrong L, Preston E, Reichert M, Phillips DL, Nisenbaum R, et al. (2000) Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clinical Infectious Diseases 31: 107-109.
9. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N, (2009) Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecologic Oncology 112: 370-376.
10. Costa S, Favato G (2008) Evaluation of the economic impact produced by the prevention of events induced by the HPV 6-11virus types contained in the quadrivalent vaccine. January 2008. Full text available for download from the Social Science Research Network (SSRN) web site: http://www.ssrn.com/abstract=1080113. Last accessed on 14/05/2012.
11. Ferrandina G, Marcellusi A, Mennini FS, Petrillo M, Di Falco C, et al. (2010) Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecologic Oncology 119: 243-249.
12. Giorgi Rossi P, Ricciardi A, Cohet C, Palazzo F, Furnari G, et al. (2009) Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 9: 71. Full text available for download from the web site: http://www.biomedcentral.com/1471-2458/9/71. Last accessed on 14/04/2012.
13. Vittori G, Matteelli A, Boselli F, Naldi L, Emberti Gialloreti L, (2008) A new approach to estimate Genital Warts incidence and prevalence in the Italian general female population. It J Gynecol Obstet 20(1): 33-42.
14. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, et al. (2010) The Health Technology Assessment of bivalent HPV vaccine Cervarix® in Italy, Vaccine 28. (19): 3379-3384.
15. Mennini FS, Costa S, Favato G, Picardo M, (2009) Anti-HPV vaccination: A review of recent economic data for Italy. Vaccine 27: A54-A61.
16. Associazione Italiana di Oncologia Medica (AIOM). Linee guida. Available online at: http://www.aiom.it/Attivit%E0Scientifica/Lineeguida/1,20,1, Last accessed on 14/05/2012.
17. Societa' Italiana di Ginecologia e Ostetricia (SIGO). Linee Guida in Oncologia Ginecologica. Available online at: http://web.tiscali.it/sigo-wolit/lineeguida1.html. Last accessed on 14/05/2012.
18. Associazione Italiana per la Ricerca sul Cancro (AIRC). Guida tumori. Tumore al pene. Available online at: http://www.airc.it/tumori/tumore-al-pene.asp#cura. Last accessed on 14/05/2012.
19. Merito M, Largeron N, Cohet C, Timelli L, Boselli F, et al. (2008) Treatment patterns and associated costs for genital warts in Italy. Curr Med Res Opin 24: 3175-3183.
20. Bishai D, Kashima H, Shah K, (2000) The cost of juvenile-onset recurrent respiratory papillomatosis. Archives of Otolaryngology - Head and Neck Surgery 126: 935-939.
21. Hu D, Goldie S, (2008) The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 198: 500.e1-500.e7e7.
22. Nomenclatore Tariffario Nazionale (2006) Gazzetta Ufficiale n. 289, 13/12/2006.
23. Ministero della Salute. Nomenclatore Tariffario. Prestazioni di assistenza specialistica ambulatoriale. Full text available for download at the Ministero della Salute web site: http://www.ministerosalute.it/imgs/C_17_bacheca_6_listaelencodocumenti_elenco0_listadocumenti_documento0_listafile_file0_linkfile.xls Last accessed on 14/05/2012. Last accessed on 14/05/2012.
24. ISTAT - The Italian National Institute of Statistics I.stat data warehouse. Available at: http://dati.istat.it/?lang=en. Last accessed on 06/07/2012.
25. Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X, (2011) Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 12: 30.
26. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Italy. Summary Report 2010. Full text available for download from the WHO's web site: http://www.who.int/hpvcentre. Last accessed on 14/05/2012.
27. Suligoi B, Salfa MC, Mariani L, (2010) Epidemiologia e management dei pazienti con condilomi genitali in Italia. Igiene e Sanità Pubblica 66: 733-756.
28. Rassu M, Bertoloni G, Mengoli C, Peron A, Benedetti P, et al. (2005) HPV genotype prevalence in cervical specimens with abnormal cytology: a report from north-east Italy. Scandinavian Journal of Infectious Diseases 37 (6-7): 476-81.
29. Ricciardi A, Largeron N, Giorgi Rossi P, et al. (2008) Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 95: 146-152.
30. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007 121: 621-632.
31. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM, (2010) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
32. Annemans L, Rémy V, Oyee J, Largeron N, (2009) Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics. 227(3): 231-45.
33. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE (2008) Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14: 244-251. Full text avaible for download from the Centers for Disease Control and Prevention website: http://wwwnc.cdc.gov/eid/article/14/2/07-0499.htm Last accessed on 14/05/2012.
34. Ronco G, Giubilato P, Naldoni C, Zorzi M, Anghinoni E, et al. (2006) Activity level and process indicators of organised programmes for cervical cancer screening in Italy. Epidemio Prev 30 (Suppl 3): 27-40.
35. Carozzi FM, Tornesello ML, Burroni E, Loguercio C, Carillo C, et al. (2010) Prevalence of human papillomavirus types in high grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev 19(9): 2389-2400.
36. Costa S, Venturoli S, Mennini FS, Marcellusi A, Pesaresi M, et al. (2011) Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study. Current Medical Research and Opinion 27(3): 569-578.
37. Agodi A, Barchitta M, La Rosa N, Cipresso R, Guarnaccia M, et al. (2009) Human papillomavirus infection: low-risk and high-risk genotypes in women in Catania, Sicily. International Journal of Gynecological Cancer 19(6): 1094-1098.
38. Silvestrini S (1999) Tumori epiteliali della Testa e del Collo. Istituto Superiore della Sanita'.Available: http://www.iss.it/lgac/docu/index.php?lang=1&tipo=32&area=91. Last accessed on 14/05/2012.
39. Hoots BE, Palefsky JM, Pimenta JM, Smith JS, (2009) Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 124: 2375-2383.
40. Abramowitz L, Rèmy V, Vainchtock A, (2010) Economic burden of anal cancer management in France. Revue d'Épidemiologie et de Santé Publique 58: 331-338.
41. Holm R, Tanum G, Karlsen F, Nesland JM, et al. (1994) Prevalence and physical state of human papillomavirus DNA in anal carcinomas. Modern Pathology 7(4): 449-453.
42. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, et al. (2004) et al.Human papillomavirus, smoking, and sexual practices in the aetiology of anal cancer. Cancer 101: 270-280.
43. Frisch M, Glimelius B, van den Brule AJC, Wohlfahrt J, Meijer CJLM, et al. (1997) Sexually Transmitted Infection as a Cause of Anal Cancer. N Engl J Med 337: 1350-1358.
44. Beckmann AM, Daling JR, Sherman KJ, Maden C, Miller BA, et al. (1989) Human papillomavirus infection and anal cancer. Int. J. Cancer 43: 1042-1049.
45. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S, (2009) Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer 124: 1626-1636.
46. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, et al. (2008) Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 113(10 suppl): 2841-28.
47. Bonvicini F, Venturoli S, Ambretti S, Paterini P, Santini D, et al. (2005) Presence and type of oncogenic human papillomavirus in classic and in differentiated vulvar intraepithelial neoplasia and keratinizing vulvar squamous cell carcinoma. J Med Virol 77(1): 102-106.
48. Lee YY, Wilczynski SP, Chumakov A, et al. (1994) Carcinoma of the vulva: HPV and p53 mutations. Oncogene 9(6): 1655-1659.
49. Engelman DE, Andrade LA, Vassallo J, (2003) Human papillomavirus infection and p53 protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. Brazilian Journal of Medical & Biological Research 36: 1159-1165.
50. Skapa P, Zamecnik J, Hamsikova E, Salakova M, Smahelova J, et al. (2007) Human papillomavirus (HPV) profiles of vulvar lesions. Possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 31: 1834-1843.
51. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM, (2009) Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors. Obstetrics & Gynecology 113(4): 917-924.
52. Daling JR, Madaleine MM, Schwarz SM, et al. (2002) A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynaecologic Oncology 84: 263-270.
53. Kreimer AR, Clifford GM, Boyle P, Franceschi S, (2005) Human Papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 14(2): 467-475.
54. Acay R, Rezende N, Fontes A, Aburad A, Nunes F, et al. (2008) Human papillomavirus as a risk factor in oral carcinogenesis: a study using in situ hybridization with signal amplification. Oral Microbiol Immunol 23: 271-274.
55. Anaya-Saavedra G, Ramirez-Amador V, Irigoyen-Camacho ME, Garcia-Cuellar CM, Guido-Jimenez M, et al. (2008) High association of human papillomavirus infection with oral cancer: a case-control study. Arch Med Res 39(2): 189-197.
56. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, et al. (2009) Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 62: 870-878 doi:10.1136/jcp.2008.063149.
57. Daling JR, Madeleini MM, Johnson LG, et al. (2005) Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. International Journal of Cancer 116(4): 606-616.
58. Tornesello ML, Duraturo ML, Losito S, Botti G, Pilotti S, et al. (2008) Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer 122(1): 132-137.
59. Lacey CJ, Lowndes CM, Shah KV, (2006) Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(suppl. 3): S35-S41.
60. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV, (2003) Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101(4): 645-652.
61. Shykhon M, Kuo M, Pearman K, (2002) Recurrent respiratory papillomatosis. Clinical Otolaryngology and Allied Sciences 27: 237-243.
62. McClay JE (2008) Recurrent Respiratory Papillomatosis Surgery. Available at: http://emedicine.medscape.com/article/865758-overview. Last accessed on 14/05/2012.